Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock
Over the past year, many Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) insiders sold a significant stake in the company which may have piqued investors' interest. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, shareholders should take a deeper look if several insiders are selling stock over a specific time period.
在过去的一年中,许多Alnylam制药公司(纳斯达克股票代码:ALNY)内部人士出售了该公司的大量股份,这可能激起了投资者的兴趣。在分析内幕交易时,了解内部人士是否在买入通常比知道他们是否在卖出更有价值,因为后者发出的信息模棱两可。但是,股东应更深入地研究是否有几位内部人士在特定时间段内出售股票。
While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.
尽管在长期投资方面,内幕交易并不是最重要的事情,但我们确实认为密切关注内部人士的所作所为是完全合乎逻辑的。
The Last 12 Months Of Insider Transactions At Alnylam Pharmaceuticals
Alnylam Pharmicals 过去 12 个月的内幕交易
The CEO & Director, Yvonne Greenstreet, made the biggest insider sale in the last 12 months. That single transaction was for US$1.5m worth of shares at a price of US$197 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$150. So it may not tell us anything about how insiders feel about the current share price.
首席执行官兼董事伊冯娜·格林斯特里特进行了过去12个月来最大规模的内幕出售。这笔单笔交易是价值150万美元的股票,每股价格为197美元。虽然我们通常不喜欢看到内幕销售,但更令人担忧的是是否以较低的价格进行销售。好消息是,此次大宗销售远高于当前150美元的价格。因此,它可能无法告诉我们内部人士对当前股价的看法。
Alnylam Pharmaceuticals insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
去年,Alnylam Pharmicals内部人士没有购买任何股票。您可以看到下图所示的去年的内幕交易(公司和个人)。如果你点击图表,你可以看到所有的个人交易,包括股价、个人和日期!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240307/0-074ad00938bbb7531be9e1532e459223-0-79a9fb60279ad6e76395d6686c584d9b.png/big)
If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.
如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。
Alnylam Pharmaceuticals Insiders Are Selling The Stock
Alnylam 制药业内部人士正在出售该股
The last quarter saw substantial insider selling of Alnylam Pharmaceuticals shares. Specifically, insiders ditched US$1.5m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.
上个季度,Alnylam Pharmicals的股票出现了大量内幕抛售。具体而言,内部人士在那段时间抛售了价值150万美元的股票,我们没有记录任何购买记录。这可能表明一些内部人士认为股票并不便宜。
Insider Ownership Of Alnylam Pharmaceuticals
Alnylam 制药公司的内部所有权
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Alnylam Pharmaceuticals insiders own about US$65m worth of shares. That equates to 0.3% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
许多投资者喜欢查看公司内部人士拥有多少股份。较高的内部所有权通常会使公司领导层更加关注股东的利益。Alnylam制药内部人士拥有价值约6500万美元的股票。这相当于该公司的0.3%。这种内部所有权水平不错,但还没有特别突出。这无疑表明了一定程度的一致性。
So What Does This Data Suggest About Alnylam Pharmaceuticals Insiders?
那么,这些数据对Alnylam制药业内部人士有何启示呢?
Insiders haven't bought Alnylam Pharmaceuticals stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. Insiders own shares, but we're still pretty cautious, given the history of sales. We'd practice some caution before buying! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 2 warning signs for Alnylam Pharmaceuticals (of which 1 is potentially serious!) you should know about.
内部人士在过去三个月中没有购买过Alnylam Pharmicals的股票,但出现了一些抛售。而且,即使我们看看去年,我们也没有看到任何购买。内部人士拥有股票,但考虑到销售历史,我们仍然相当谨慎。购买前我们会谨慎行事!因此,虽然了解内部人士在买入或卖出方面的所作所为很有帮助,但了解特定公司面临的风险也很有帮助。每家公司都有风险,我们发现了 Alnylam Pharmicals 的 2 个警告信号(其中 1 个可能很严重!)你应该知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。